SAN FRANCISCO, CA--(Marketwire - Nov 9, 2012) - Expression Analysis (EA), a Quintiles Company, has raised more than $27,000 for the UCSF Benioff Children's Hospital at the 62nd Annual Meeting of the American Society of Human Genetics (ASHG) in San Francisco. The donation benefits the pediatric genetics division, which allows researchers to diagnose childhood diseases more precisely, predict their course, and create more effective treatments with fewer side effects.
EA's "Leave Your Fingerprint on the Cure" campaign asked ASHG attendees to help complete a mural to earn corporate donations for the hospital. Each person who painted a flower and left his or her fingerprint on a large mural triggered a $75 donation to the UCSF Benioff Children's Hospital. This is EA's fifth year at ASHG hosting this campaign, which has generated more than $150,000 for pediatric genetics research. The campaign is one of many programs that EA leads to aid academic and industry researchers in uncovering genetic markers linked to complex diseases.
"We are honored that EA has chosen to support UCSF Benioff Children's Hospital, notably our Division of Pediatric Genetics through this unique fundraising initiative," said Anthony Wynshaw-Boris, MD, Chief, Pediatric Genetics, UCSF Benioff Children's Hospital. "The generous donation will help our researchers continue the important work in better understanding genetic disease and developing new therapies."
"EA's Leave Your Fingerprint on the Cure campaign has grown exponentially over the past five years, with donations up from $10 per fingerprint in 2008 to $75 today. Through the help of our corporate sponsors, the campaign has raised more than $150,000 for research in pediatric medical genetics for seven hospitals across the United States," said Steve McPhail, President and CEO of EA. "I sincerely thank this year's cosponsors Illumina, Raindance Technologies, Life Technologies, Fluidigm, Qiagen, Golden Helix and Ingenuity. This campaign has become an important part of who EA is -- a company dedicated to providing industry-leading tools and services that accelerate the pace of genetic research leading to improved diagnosis, treatment and management of complex disease."
EA, a Quintiles company, provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world's largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. All projects are conducted under clinical-grade quality control, ensured through CLIA certification, GLP compliance, and adherence to CLSI guidelines. EA's bioinformatics staff are key contributors to the Food and Drug Administration's MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than $2.2 million towards academic genomic research grants, including more than $150,000 as part of the "Leave Your Fingerprint on the Cure" Campaign for pediatric genetic research hosted at the American Society for Human Genetics annual meeting.
Quintiles is the world's leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.